Pacira BioSciences, Inc. (PCRX) News
Filter PCRX News Items
PCRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PCRX News Highlights
- For PCRX, its 30 day story count is now at 3.
- Over the past 24 days, the trend for PCRX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- RBC are the most mentioned tickers in articles about PCRX.
Latest PCRX News From Around the Web
Below are the latest news stories about PACIRA BIOSCIENCES INC that investors may wish to consider to help them evaluate PCRX as an investment opportunity.
Why Is Pacira (PCRX) Down 11.8% Since Last Earnings Report?Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Pacira BioSciences to Participate in Fireside Chat at the 2023 Jefferies Healthcare ConferenceTAMPA, Fla., May 31, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2023 Jefferies Healthcare Conference at 9:30 AM ET on Wednesday, June 7, 2023 in New York. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. About Pacira Pacira BioSciences, Inc. (Nas |
Pacira BioSciences to Participate in Fireside Chat at the 2023 RBC Capital Markets Global Healthcare ConferenceTAMPA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2023 RBC Capital Markets Global Healthcare Conference at 3:05 PM ET on Tuesday, May 16, 2023 in New York. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. About Pacira Pacira BioScie |
Q1 2023 Pacira Biosciences Inc Earnings CallQ1 2023 Pacira Biosciences Inc Earnings Call |
Why Pacira BioSciences Shares Are Trading Lower TodayPacira BioSciences Inc (NASDAQ: PCRX) reported Q1 sales of $160.3 million compared to $158.0 million a year ago and the consensus of $158.84 million. The sales fell almost 7% sequentially from $172 million in Q4 FY22. Exparel sales reached $130.4 million, slightly above the $129.2 million reported a year ago and down from $138.0 million in Q4. Q1 average daily volume growth of 6% was offset by a lower net selling price primarily due to the implementation of 340B Drug Pricing and other contracted |
Pacira (PCRX) Q1 Earnings Miss Estimates, Revenues BeatPacira (PCRX) misses on Q1 earnings but beats on revenues, even though volume growth of Exparel is offset by lower selling prices. |
Pacira BioSciences Reports First Quarter 2023 Financial Results-- EXPAREL continues to outperform elective surgery market with average daily volumes up 6 percent over prior year -- -- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., May 03, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the first quarter of 2023. First Quarter 2023 Financial Highlights Total revenues of $160.3 millionNet product |
Pacira to Report First Quarter 2023 Financial Results on Wednesday May 3, 2023TAMPA, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on Wednesday, May 3, 2023. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing |
A Look At The Fair Value Of Pacira BioSciences, Inc. (NASDAQ:PCRX)Key Insights Using the 2 Stage Free Cash Flow to Equity, Pacira BioSciences fair value estimate is US$54.97 With... |
Pacira BioSciences Partners with The Invited Celebrity Classic – a PGA TOUR Champions Event – to Make iovera° The Official Non-Opioid Pain Management PartnerPGA TOUR Champions Golfer, Paul Goydos, Promotes Further Awareness of Non-Opioids with 2023 PartnershipTAMPA, Fla. and IRVING, Texas, April 20, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc., the industry leader in its commitment to non-opioid pain management and regenerative health solutions, and the Invited Celebrity Classic, an officially sanctioned PGA TOUR Champions event, today announced a partnership naming Pacira’s pain management device, iovera°, as The Official Non-Opioid Pain Manag |